Influence of ethylmethylhydroxypyridine succinate inclusion in antihypertensive therapy on the condition of the arterial wall in young patients with hypertension

Abstract

The purpose of the study was to evaluate the impact of combined antihypertensive therapy including ethylmethylhydroxypyridine succinate on blood pressure levels, arterial stiffness and quality of life in young patients with hypertension. A total of 60 patients (mean age, 41.7±1.3 years) with grade 2 hypertension who were not taking regular antihypertensive therapy were examined. After baseline data collection, 30 patients (group 1) were administered basic therapy with antihypertensive drugs and ethylmethylhydroxypyridine succinate, and 30 patients (group 2) were administered basic therapy, which included a combination of lisinopril 10–20 mg/day and amlodipine 5–10 mg/day for 8 weeks. After the treatment, a decrease in systolic and diastolic blood pressure levels in groups 1 and 2 by 23.3 mm Hg and 17.5 mm Hg and 14.3 mm Hg and 8.4 mm Hg, respectively, was observed (all p<0.05). It was found that average daily levels of systolic and diastolic blood pressure were 7.1 % and 10.8 % (p<0.05) lower in the patients of group 1 compared to group 2 and had a positive effect on daily BP profiles. A more significant decrease in the pulse wave velocity in the aorta was observed (2.1±0.5 m/s, p<0.05) in group 1, while in group 2 this parameter decreased by (1.5±0.5 m/s, p<0.05). There was an improvement in the scale scores representing physical health, working capacity, psychological abilities, degree of severity of negative psychological state, as well as the ability to social contacts more expressed in group 1. Therefore, inclusion of ethylmethylhydroxypyridine succinate in the therapeutic complex in young patients with hypertension increases efficacy of antihypertensive therapy, improves daily blood pressure profiles and positively affects the quality of life in this category of patients.